Factor H / Complement Factor H (BSB-164), MMab

Description

Factor H or Complement Factor H (CFH), is the major soluble inhibitor of complement, where its binding to self markers (i.e. particular glycan structures) prevents complement activation and amplification on host surfaces. Mutations and polymorphisms that affect recognition of self markers by Factor H are associated with diseases of complement dysregulation, such as age-related macular degeneration and atypical hemolytic uremic syndrome. In addition, pathogens and cancer cells can hijack Factor H to evade the immune response. Lung, Ovarian, Glial and Colon Cancer cells show enhanced expression and surface binding of soluble regulators, including Factor H. Factor H antibody has been shown to be expressed by human Breast Cancer cells, which correlates with the presence of immunosuppressive macrophages, Breast Cancer recurrence and severity of the disease. Lung cancer cells may develop a protective mechanism against complement attack by expressing and binding Factor H to their cell membranes. Additionally, it has been demonstrated that Factor H is upregulated by constitutive activation of STAT4, which is accounted for by SOCS silencing in Lung Cancer cells. Several studies have also suggested the importance of Factor H in the protection of tumor cells against complement activation. The importance of Factor H antibody expression for the protection of cancer cells in vivo will help to elucidate the mechanisms used by tumor cells to avoid complement activity and assist in the design of more efficient complement-mediated immunotherapies.

Caractéristiques

Type

Mouse Monoclonal

Clone

BSB-164

Isotype

IgG1

Réactivité

Paraffin, Frozen

Localisation

Cytoplasmic, Membranous

Contrôle

Testis, Liver, Kidney, Pancreas, Adrenal Gland

Usage prévu

For In Vitro Diagnostic Use